| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1378/CHEST.89.4_SUPPLEMENT.225S |
| P698 | PubMed publication ID | 3514171 |
| P2093 | author name string | Mountain CF | |
| P433 | issue | 4 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 225S-233S | |
| P577 | publication date | 1986-04-01 | |
| P1433 | published in | Chest | Q5093377 |
| P1476 | title | A new international staging system for lung cancer | |
| P478 | volume | 89 |
| Q41696754 | "Incomplete resection" in non-small cell lung cancer: need for a new definition. Canadian Lung Oncology Group |
| Q74652194 | A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers |
| Q39795668 | A comparison between clinical decisions made about lung cancer patients and those inherent in the corresponding Scottish Intercollegiate Guidelines Network (SIGN) guideline. |
| Q50976951 | A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. |
| Q35938690 | A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma |
| Q37682246 | A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer |
| Q33331232 | A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group |
| Q33495664 | A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group |
| Q33341441 | A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer |
| Q36114656 | A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group |
| Q73486265 | A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis |
| Q33504172 | A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report |
| Q33664774 | A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy |
| Q73454715 | A practical prognostic index for inoperable non-small-cell lung cancer |
| Q67488501 | A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy |
| Q36615878 | A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. |
| Q68241117 | A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer |
| Q72012065 | A randomised trial of two cisplatin-containing chemotherapy regimens in patients with Stage III-B and IV non-small cell lung cancer |
| Q68454957 | A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group |
| Q40933452 | A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma |
| Q37368084 | A treatment trade-off based decision aid for patients with locally advanced non-small cell lung cancer |
| Q28327044 | Adjuvant Chemotherapy for T1-2NOMO Small Cell Lung Cancer: Single-Agent or Combination Chemotherapy? |
| Q36521844 | Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future |
| Q73488908 | Adjuvant chemotherapy for non-small cell lung cancer |
| Q71170156 | Adoptive immunotherapy for nonsmall cell lung carcinoma. A fourth treatment modality, complicated radiation sensitizer, or none of the above |
| Q74505907 | Advanced non-small cell lung cancer chemotherapy: a randomized trial of two active regimens (MVP and PE) |
| Q44427270 | Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). |
| Q33883308 | Age does not influence early and late tumor-related outcome for bronchogenic carcinoma |
| Q53061715 | Aldehyde dehydrogenases in early stage lung cancer: nuclear expression. |
| Q53457377 | Alteration of the p53 gene of lung carcinomas with sarcomatous transformation (spindle cell carcinoma): analysis of four cases. |
| Q34423364 | Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas |
| Q77747779 | Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma |
| Q69842706 | Alveolar cell carcinoma of the lung: a retrospective analysis of 205 patients |
| Q36615525 | An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer |
| Q40408812 | An historical perspective of multi-modality treatment for resectable non-small cell lung cancer |
| Q38001028 | An integrated approach to evaluation of the solitary pulmonary nodule |
| Q74626694 | Analysis of lobectomy for small peripheral lung cancer supports extended segmentectomy |
| Q52267080 | Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma. |
| Q72293353 | Anatomic basis of lymphatic spread from carcinoma of the lung to the mediastinum: surgical and prognostic implications |
| Q72563105 | Anatomic basis of lymphatic spread of lung carcinoma to the mediastinum: anatomo-clinical correlations |
| Q74423639 | Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer |
| Q34666401 | Angiogenesis inhibitors in lung cancer |
| Q73400496 | Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer |
| Q73793628 | Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small-cell lung cancer |
| Q71843745 | Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer |
| Q40887493 | Approach to the solitary pulmonary nodule |
| Q40484071 | Are bilobectomies acceptable procedures? |
| Q71653842 | Associated primary esophageal and lung carcinoma: A study of 39 patients |
| Q54936006 | Association between smoking and tumor progression in Japanese women with adenocarcinoma of the lung. |
| Q46173861 | Association of L-myc polymorphism with lung cancer susceptibility and prognosis in relation to age-selected controls and stratified cases |
| Q73354557 | Association of p53 protein expression in stage I lung adenocarcinoma with reference to cytological subtypes |
| Q34450520 | Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. |
| Q72112092 | Biopsy of Lesions of the Thorax |
| Q52237367 | Blood analyses and survival in symptom- and survey-detected lung cancer patients |
| Q46731284 | Blood analyses as prognostic factors in primary lung cancer |
| Q40795687 | Bronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survival |
| Q81058216 | Bronchoplastic and pulmonary arterioplastic procedures in the treatment of bronchogenic carcinoma |
| Q34569389 | Building a better therapy for stage IIIA non-small cell lung cancer |
| Q34124421 | C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. |
| Q68136621 | Carcinoma of the lung |
| Q36555770 | Carcinoma of the lung. Who will benefit from surgery? |
| Q44475954 | Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression |
| Q35896484 | Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden |
| Q73481985 | Chemotherapy for advanced non-small cell lung cancer |
| Q38296618 | Chemotherapy of non-small cell lung cancer |
| Q43680179 | Chemotherapy versus best supportive care in stage IV non-small cell lung cancer, non metastatic to the brain |
| Q71309444 | Chest wall invasive non-small cell lung cancer: patterns of failure and implications for a revised staging system |
| Q67912670 | Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell carcinoma of the lung |
| Q74597265 | Clinical analysis of small-sized peripheral lung cancer |
| Q72149455 | Clinical studies of irinotecan alone and in combination with cisplatin |
| Q40632046 | Clinical utility of cytologic typing of lung tumors |
| Q72950056 | Combined modality therapy for stage IIIA non-small cell carcinoma of the lung |
| Q40408831 | Combined modality treatment for stage III non-small cell lung cancer |
| Q77337896 | Combined-modality treatment for stage IIIa (N2) non-small cell lung cancer: a National Cancer Institute Intergroup study |
| Q36695064 | Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer |
| Q73090119 | Comparison of the surgical results of lobectomy with bronchoplasty and pneumonectomy for lung cancer |
| Q35657192 | Concomitant cardiac and pulmonary operations for lung cancer |
| Q33499749 | Concurrent carboplatin, etoposide and thoracic radiation for poor-risk Stage III non-small-cell lung carcinoma: A pilot study |
| Q51709461 | Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. |
| Q24245635 | Concurrent chemoradiotherapy in non-small cell lung cancer |
| Q74662687 | Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation in stage III non-small cell lung cancer |
| Q73677979 | Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer |
| Q35017967 | Consensus conference on medical treatment of non-small cell lung cancer: adjuvant treatment |
| Q67802080 | Contrast-enhanced MRI for the staging of bronchogenic carcinoma: Comparison with CT and histopathologic staging — Preliminary results |
| Q35226646 | Controversies in the Nonsurgical Treatment of Stage III Non-small Cell Lung Cancer |
| Q67915731 | Controversies in the role of postoperative radiotherapy in stages II and IIIa resected non-small cell lung carcinoma |
| Q72095533 | Correlation between increased granulocyte elastase release and activation of blood coagulation in patients with lung cancer |
| Q38630276 | Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis |
| Q35168071 | Current Options in the Treatment of Non-Small Cell Lung Cancer |
| Q37073202 | Current concepts in the management of small cell lung cancer |
| Q36350384 | Current morbidity, mortality, and survival after bronchoplastic procedures for malignancy |
| Q38566507 | Current treatment of unresectable lung cancer |
| Q41150455 | Cutaneous response to intradermal histamine in lung cancer |
| Q36641208 | Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer |
| Q68494073 | Cytogenetics of non-small cell lung cancer: analysis of consistent non-random abnormalities |
| Q47947877 | DNA amplification on chromosome 6p12 in non small cell lung cancer detected by arbitrarily primed polymerase chain reaction |
| Q44014063 | Define relative incomplete resection by highest mediastinal lymph node metastasis for non-small cell lung cancers: Rationale based on prognosis analysis |
| Q40829473 | Detection of occult metastases in lung carcinomas: progress and implications for lung cancer staging |
| Q72236402 | Detection of oligoclonal T lymphocytes in lymph nodes draining from advanced non-small-cell lung cancer |
| Q34951761 | Diagnosis and management of early lung cancer |
| Q33890714 | Diagnosis and staging of lung cancer |
| Q74069069 | Diagnosis of visceral pleural invasion in resected lung cancer using a jet stream of saline solution |
| Q73347732 | Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients |
| Q30655982 | Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases |
| Q69250345 | Diagnostic and therapeutic uses of pleuroscopy (thoracoscopy) in lung cancer |
| Q53861994 | Differential expression of senescence and cell death factors in non-small cell lung and colorectal tumors showing telomere attrition. |
| Q78192011 | Does an incomplete interlobar fissure influence survival or recurrence in resected non-small-cell lung cancer? |
| Q57763264 | Does the use of immunohistochemistry to identify micrometastases provide useful information in the staging of node-negative non-small cell lung carcinomas? |
| Q73203626 | Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer |
| Q73283383 | Early complications in surgical treatment of lung cancer: a prospective, multicenter study. Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española de Neumología y Cirugía Torácica |
| Q44557538 | Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer |
| Q42714896 | Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating lung cancer recurrence |
| Q58454754 | Efficiency of serum copper/zinc ratio for differential diagnosis of patients with and without lung cancer |
| Q34014738 | Emphysema as a risk factor for the outcome of surgical resection of lung cancer. |
| Q67664253 | Endobronchial radiation therapy (EBRT) in the management of lung cancer |
| Q70636659 | Epidermal growth factor receptor and lipid membrane components in human lung cancers |
| Q78213676 | Evaluation of TMN classification for lung carcinoma with ipsilateral intrapulmonary metastasis |
| Q36648454 | Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer |
| Q77361527 | Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer |
| Q44929344 | Evaluation of serum ca 125 as a tumor marker in non-small cell lung cancer |
| Q53348046 | Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party. |
| Q69250326 | Evaluation of the mediastinum by invasive techniques |
| Q42400026 | Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer |
| Q41153716 | Expression of Blood-Group Antigen A — A Favorable Prognostic Factor in Non-Small-Cell Lung Cancer |
| Q42518277 | Expression of E-selectin, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 in non-small-cell lung carcinoma |
| Q73275702 | Expression of PDGF, IGF-II, bFGF and TGF-beta 1 in pulmonary adenocarcinoma |
| Q44116024 | Expression of bcl-2 protein in stage T1NOMO non-small cell lung carcinoma |
| Q58454730 | Expression of human telomerase subunit genes in primary lung cancer and its clinical significance |
| Q55112405 | Expression of thymidylate synthase in human non-small cell lung cancer. |
| Q73016439 | Extended resection for lung cancer invading mediastinal organs |
| Q40816069 | External beam radiation therapy alone for loco-regional recurrence of non-small-cell lung cancer after complete resection |
| Q34872169 | External beam radiation therapy for bronchial stump recurrence of non-small-cell lung cancer after complete resection |
| Q35101606 | Extracranial stereotactic radiation delivery: expansion of technology beyond the brain |
| Q32061854 | FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations |
| Q73137241 | Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma |
| Q43743358 | Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy |
| Q31992270 | Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). |
| Q42931937 | Favorable outcome using a maze procedure for left pneumonectomy combined with resection of the left atrium in stage IIIB lung cancer |
| Q71046661 | Fine tuning of epitopic dominance induced by lung cancer on the IgG response to bovine betalactoglobulin: towards a paraneoplastic immune marker |
| Q33378130 | From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer |
| Q35550676 | Functional imaging in lung cancer |
| Q40408807 | Future directions in non-small cell lung cancer. A personal view. |
| Q36643732 | Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer |
| Q36114860 | Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus |
| Q39478999 | Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. |
| Q48129987 | Helical tomotherapy for solitary lung tumor: feasibility study and dosimetric evaluation of treatment plans |
| Q33775974 | High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation |
| Q58215297 | High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma |
| Q33396259 | High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group |
| Q43584700 | Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial |
| Q52207721 | Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer. |
| Q36136129 | Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers |
| Q77068387 | Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia |
| Q36621064 | Immunohistochemical analysis of Bcl-2 protein in early squamous cell carcinoma of the bronchus treated with photodynamic therapy |
| Q72301713 | Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer |
| Q73158363 | Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival |
| Q35832962 | Immunohistochemical study of p53 in human lung carcinomas. |
| Q54113153 | Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. |
| Q77726702 | Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung |
| Q72301716 | Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. A pilot study |
| Q73466989 | Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone |
| Q43007663 | Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer |
| Q36134707 | Implicit rationing criteria in non-small-cell lung cancer treatment |
| Q35232954 | Important prognostic factors for survival in patients with malignant pleural effusion |
| Q53341193 | Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. |
| Q77121296 | Increased expression of sialyl Lewis(x) antigen is associated with distant metastasis in lung cancer patients: immunohistochemical study on bronchofiberscopic biopsy specimens |
| Q50994043 | Increased levels of serum intercellular adhesion molecule-1 (ICAM-1) in patients with non-small cell lung cancer. |
| Q33328264 | Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group |
| Q53882879 | Individualized prognosis in non-small-cell carcinoma. A multivariate approach |
| Q79278145 | Induction Therapy for Early-Stage Lung Cancer? The Rationale Behind the Question |
| Q63548348 | Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma |
| Q46104902 | Induction concurrent chemoradiotherapy compared with induction radiotherapy for superior sulcus non-small cell lung cancer: a retrospective study |
| Q73931175 | Influence of age and predicted forced expiratory volume in 1 s on prognosis following complete resection for non-small cell lung carcinoma |
| Q42439378 | Influence of cathepsin D expression in lung adenocarcinoma on prognosis: possible importance of its expression in tumor cells and stromal cells, and its intracellular polarization in tumor cells |
| Q67915790 | Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer |
| Q71094072 | Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma |
| Q33492459 | Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study |
| Q69411202 | Is CT scanning essential in the pre-operative assessment of lung cancer? |
| Q73649980 | Is prolonged survival possible for patients with supraclavicular node metastases in NSCLC treated with chemoradiotherapy? IJROBP 1999;44(4): 847-853 |
| Q40791678 | Is there a role for vindesine in the treatment of non-small cell lung cancer? |
| Q73129080 | Iterative surgical resections for local recurrent and second primary bronchogenic carcinoma |
| Q38484341 | K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma |
| Q46846464 | Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan |
| Q35123826 | Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts |
| Q77754635 | Lewis Y antigen expression and postoperative survival in non-small cell lung cancer |
| Q67508277 | Locally recurrent non-small-cell lung cancer after complete surgical resection |
| Q73965568 | Longitudinal study of resting energy expenditure, body cell mass and the inflammatory response in male patients with non-small cell lung cancer |
| Q73838386 | Loss of alpha-v integrin expression and recurrence in node-negative lung carcinoma |
| Q78765478 | Loss of heterozygosity at loci of candidate tumor suppressor genes in microdissected primary non-small cell lung cancer |
| Q52542082 | Loss of p16 and/or pRb protein expression in NSCLC. An immunohistochemical and prognostic study. |
| Q43802082 | Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma |
| Q50611835 | Lung cancer in West Sweden 1976-1985. A study of trends and survival with special reference to surgical treatment. |
| Q35122960 | Lung cancer in elderly patients. |
| Q34272157 | Lung cancer in patients under age 40. |
| Q35858070 | Lung cancer in patients with HIV Infection and review of the literature |
| Q36520328 | Lung cancer in the 1990s. |
| Q69009762 | Lung cancer in the elderly |
| Q34384387 | Lung cancer surgery--preoperative risk assessment and patient selection |
| Q34194023 | Lung cancer--bad news, good news |
| Q35232728 | Lung cancer: a review of current therapeutic modalities |
| Q45744868 | Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors |
| Q38211457 | Lymph node dissection for lung cancer: past, present, and future |
| Q71107425 | Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? |
| Q77072301 | Lymph node metastasis in small peripheral adenocarcinoma of the lung |
| Q50956477 | Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma. |
| Q43947513 | Malignant minor pleural effusion detected on thoracotomy for patients with non-small cell lung cancer: is tumor resection beneficial for prognosis? |
| Q36780606 | Management of unresected stage III non-small cell lung cancer: a systematic review. |
| Q42735896 | Managing patients with lung cancer. New guidelines should improve standards of care |
| Q36079799 | Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay |
| Q71827870 | Measurements of hormonal peptides in the bronchoalveolar fluid as tumor markers of lung cancer |
| Q45181815 | Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group |
| Q47356218 | Mediastinal lymph node size in an Asian population |
| Q45236726 | Mediastinal staging in non-small-cell lung cancer |
| Q41519936 | Mediastinoscopy, thoracoscopy, and video-assisted thoracic surgery in the diagnosis and staging of lung cancer |
| Q55208721 | Meet the new boss: lung cancer staging. |
| Q47340657 | Mental adjustment after surgery for non-small cell lung cancer |
| Q44062373 | Mental state as a possible independent prognostic variable for survival in patients with advanced lung carcinoma |
| Q41519054 | Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung--a study from a cohort of 259 consecutive patients treated with chemotherapy |
| Q50882869 | Microalbuminuria in patients with lung cancer. |
| Q58454740 | Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer |
| Q77531679 | Microsatellite alterations and p53, TGFbetaRII, IGFIIR and BAX mutations in sporadic non-small-cell lung cancer |
| Q34465186 | Minimal residual disease in non-small-cell lung cancer |
| Q71518207 | Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis |
| Q36967155 | Modern management of small-cell lung cancer |
| Q73544485 | Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer |
| Q77530365 | Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis |
| Q35832451 | Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data |
| Q58454741 | Mutations of the p53 tumor suppressor gene as clonal marker for multiple primary lung cancers |
| Q67491042 | Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer |
| Q40715191 | Neoadjuvant and adjuvant therapy in the management of locally advanced non-small-cell lung cancer |
| Q36431673 | Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression |
| Q37449019 | New TNM classification for non-small-cell lung cancer |
| Q38087689 | New era of radiotherapy: an update in radiation-induced lung disease. |
| Q41175610 | Non-AIDS-defining cancers |
| Q70169812 | Non-small cell lung cancer |
| Q36404552 | Non-small cell lung cancer part: I Biology, diagnosis, and staging |
| Q40912868 | Non-small cell lung cancer: an overview of current management |
| Q41523353 | Non-small cell lung cancer: clinical value of new biological predictors |
| Q70189510 | Non-small cell lung cancer: issues in diagnosis, staging and treatment |
| Q77815143 | Non-small cell lung cancer: report on the 5th central European lung cancer conference |
| Q40401396 | Non-small-cell lung carcinoma. Current and future therapeutic management |
| Q33902547 | Novel approaches to locally advanced unresectable non-small cell lung cancer |
| Q39192389 | Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. |
| Q72427599 | Oncogene overexpression in non-small-cell lung cancer tissue: prevalence and clinicopathological significance |
| Q41106410 | Oncology imaging: nodal spread-intrathoracic nodes |
| Q41144282 | Ongoing clinical trials in lung cancer. |
| Q74519265 | Operative approach for multiple primary lung carcinomas |
| Q35828425 | Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. |
| Q92619296 | Outcomes comparison between neoadjuvant chemotherapy and adjuvant chemotherapy in stage IIIA non-small cell lung cancer patients |
| Q39989754 | P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer |
| Q40404000 | Palliative surgery for thoracic malignancies |
| Q80100950 | Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? |
| Q58410698 | Paraneoplastic syndromes in 68 cases of resectable non-small cell lung carcinoma: can they help in early detection? |
| Q36476212 | Patient outcomes of monotherapy with hypofractionated three-dimensional conformal radiation therapy for stage T2 or T3 non-small cell lung cancer: a retrospective study |
| Q33733187 | Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials |
| Q33728660 | Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancer |
| Q35977364 | Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer |
| Q33329120 | Phase I and pharmacologic study of oral (E)-2'-deoxy-2'-(fluoromethylene) cytidine: on a daily x 5-day schedule |
| Q33627751 | Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. |
| Q43812441 | Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer |
| Q33498614 | Phase I-II trial of concomitant continuous carboplatin (CBDCA) infusion and radiotherapy in advanced nonsmall cell lung cancer with evaluation for surgery: final report |
| Q36619185 | Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer |
| Q68492902 | Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer |
| Q33494063 | Phase II study of 4'-iodo-4'-deoxydoxorubicin in non-resectable non-small-cell lung cancer |
| Q33348521 | Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer |
| Q73580666 | Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer |
| Q46806310 | Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer |
| Q36858092 | Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer |
| Q47346175 | Physician support and patient psychologic responses after surgery for nonsmall cell lung carcinoma: a prospective observational study |
| Q55039151 | Pleural lavage cytology immediately after thoracotomy as a prognostic factor for patients with lung cancer. |
| Q74387112 | Pneumonectomy for non-small cell lung cancer: predictors of operative mortality and survival |
| Q77068356 | Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up |
| Q67912725 | Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment |
| Q36135184 | Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer |
| Q69806107 | Preoperative and adjuvant chemotherapy in locally advanced non-small cell lung cancer |
| Q42418667 | Preoperative screening for metastases in lung cancer |
| Q52930505 | Presenting manifestations, cigarette smoking, and detection bias in age at diagnosis of lung cancer. |
| Q41523310 | Pretreatment minimal staging and prognostic factors for non-small cell lung cancer |
| Q50988976 | Prevalence and prognostic significance of proteinuria in patients with lung cancer. |
| Q50855849 | Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. |
| Q36231186 | Primary lung cancer in young patients: A study of 82 surgically treated patients |
| Q36135232 | Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase |
| Q36500218 | Prognosis in lung cancer: physicians' opinions compared with outcome and a predictive model |
| Q78055478 | Prognosis of completely resected pN2 non-small cell lung carcinomas: What is the significant node that affects survival? |
| Q67489350 | Prognostic Factors in Lung Cancer |
| Q28281809 | Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993 |
| Q37767305 | Prognostic classifications of lymph node involvement in lung cancer and current International Association for the Study of Lung Cancer descriptive classification in zones |
| Q51356299 | Prognostic factors in lung cancer in a defined geographical area over two decades with a special emphasis on gender. |
| Q37929588 | Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables |
| Q48138746 | Prognostic factors in surgical treatment of solitary brain metastasis after resection of non-small-cell lung cancer |
| Q71755442 | Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage |
| Q73209595 | Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy |
| Q77602875 | Prognostic implications of pulmonary satellite nodules: are the 1997 staging revisions appropriate? |
| Q41519933 | Prognostic markers in resectable non-small cell lung cancer |
| Q43531194 | Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung |
| Q54771804 | Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. |
| Q35224746 | Prognostic significance of massive bronchogenic tumor embolus |
| Q77197687 | Prognostic significance of thrombomodulin expression and vascular invasion in stage I squamous cell carcinoma of the lung |
| Q44344425 | Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence |
| Q83696257 | Prognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be? |
| Q74752275 | Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features |
| Q36115963 | Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer |
| Q50944026 | Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma. |
| Q73821349 | Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung |
| Q77615131 | Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas: role of subcarinal nodes in selective dissection |
| Q39529026 | Quality of life during chemotherapy in non-small cell lung cancer patients |
| Q73226531 | Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR |
| Q79745325 | Radiation therapy |
| Q35543221 | Radiation therapy alone in early stage non‐small cell lung cancer |
| Q77344419 | Radiation therapy of stage I and II non-small cell lung cancer (NSCLC) |
| Q38692537 | Radiographic evaluation of chest-wall lesions |
| Q42050769 | Radiologic staging of lung carcinoma: a report generator and database system |
| Q74619608 | Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer |
| Q43960299 | Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung |
| Q73090117 | Radiotherapy and concurrent continuous infusion of cisplatin with adjuvant surgery in nonresectable Stage III lung carcinoma: short- and long-term results of a Phase II study |
| Q62517817 | Radiotherapy versus follow-up in the treatment of pathological stage Ia and Ib non-small cell lung cancer. Early stopped analysis of a randomized controlled study✩ |
| Q37355007 | Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer |
| Q44405219 | Randomized Double-Blind Placebo-Controlled Trial of Bestatin in Patients With Resected Stage I Squamous-Cell Lung Carcinoma |
| Q53412730 | Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). |
| Q73486261 | Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation therapy oncology group (RTOG) 92-04 |
| Q46700637 | Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: Results of a phase I/II study |
| Q46684570 | Recent Outcomes for Patients with Carcinoma of the Lung |
| Q36869597 | Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer |
| Q36694127 | Relationship between 3p deletions and telomerase activity in non-small-cell lung cancer: prognostic implications |
| Q44007436 | Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors |
| Q72595444 | Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group |
| Q53343111 | Results of surgery for primary lung cancer based on the new international staging system. |
| Q73705749 | Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer |
| Q33698439 | Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer |
| Q37065488 | Role of gender in the survival of surgical patients with nonsmall cell lung cancer |
| Q35753272 | Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer |
| Q77324133 | Role of pleural lavage cytology before resection for primary lung carcinoma |
| Q24633254 | Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data |
| Q40854175 | Role of radiation therapy in the management of lung cancer |
| Q36670950 | Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers |
| Q53064719 | Routine use of dual time ¹⁸F-FDG PET for staging of preoperative lung cancer: does it affect clinical management? |
| Q67720553 | Sarcomatoid carcinoma of the lung. Immunohistochemieal and ultrastructural studies of 14 cases |
| Q47602832 | Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer |
| Q40775727 | Sequential combination chemotherapy and radiotherapy in locally advanced non-small cell carcinoma of the bronchus |
| Q71863856 | Serum Level and Tissue Expression of c-erbB-2 Protein in Lung Adenocarcinoma |
| Q71842951 | Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer |
| Q41084755 | Significance of Perioperative Blood Transfusions in Patients Undergoing Resection of Stage I and II Non-small-cell Lung Cancers |
| Q67485565 | Small Cell Lung Cancer Presenting as a Solitary Pulmonary Nodule |
| Q74235823 | Small cell lung cancer I--III A: cytoreductive chemotherapy followed by resection with continuation of chemotherapy |
| Q73568284 | Small-cell nonanaplastic bronchogenic carcinoma. The new stage I |
| Q77150008 | Spiral CT: thoracic applications |
| Q72683690 | Sputum cytology |
| Q37100089 | Squamous cell carcinoma antigen as an adjunct tumour marker in primary carcinoma of the lung |
| Q77380388 | Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening |
| Q41159739 | Stage-directed treatment guidelines |
| Q72244522 | Staging and management of lung cancer: sleeve resection |
| Q33943900 | Staging and the surgical management of lung cancer |
| Q34569366 | Staging classification of lung cancer. A critical evaluation |
| Q26863443 | Staging lymph node metastases from lung cancer in the mediastinum |
| Q70474480 | Staging non-small cell lung cancer |
| Q69264452 | Staging of lung cancer |
| Q34447441 | Staging of non-small cell lung cancer: consensus, controversies and challenges |
| Q40633491 | Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? |
| Q40853281 | Staging systems of lung cancer |
| Q36729269 | Staging: The key to rational management of lung cancer |
| Q37038910 | Stereotactic body radiation therapy for early-stage non-small-cell lung cancer |
| Q51023039 | Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. |
| Q44765182 | Superoxide anion-generating activity of polymorphonuclear leukocytes and monocytes in patients with lung cancer |
| Q24247318 | Surgery for early stage non-small cell lung cancer |
| Q35543211 | Surgery for early stage non‐small cell lung cancer |
| Q24245182 | Surgery for local and locally advanced non-small cell lung cancer |
| Q74108094 | Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend |
| Q41159746 | Surgical approaches in special situations |
| Q52905642 | Surgical management of adrenal metastases from lung cancer. |
| Q80492080 | Surgical management of lung cancer |
| Q39647265 | Surgical management of lung cancer with solitary cerebral metastasis |
| Q50973793 | Surgical results and prognostic factors in early non-small cell lung cancer. |
| Q74387117 | Surgical results for multiple primary lung cancers |
| Q77639203 | Surgical results of maximal local-regional treatment (cisplatin-enhanced high-dose radiotherapy and adjuvant surgery) in initially non-resectable stage III lung cancer |
| Q68306888 | Surgical treatment of bronchogenic carcinoma: A retrospective study of 720 thoracotomies |
| Q48583074 | Surgical treatment of stage III non-small cell bronchogenic carcinoma involving the chest wall |
| Q73348048 | Surgically Proven Complete Response of Stage III Non-Small Cell Lung Cancer after Cisplatin-Enhanced Radiotherapy. Clinical Implications and Long-Term Results |
| Q67485523 | Surgically resected lung cancer in young adults |
| Q38031422 | Surveillance of resected non-small cell lung cancer |
| Q33257648 | Survival Characteristics after Neodymium: YAG Laser Photoresection in Advanced Stage Lung Cancer |
| Q73542793 | Survival and prognosis after pneumonectomy for lung cancer in the elderly |
| Q77758307 | Survival and risk model for stage IB non-small cell lung cancer |
| Q40465859 | Survival in early-stage non-small cell lung cancer |
| Q44456254 | Survival in resected stage I lung cancer with residual tumor at the bronchial resection margin |
| Q44319686 | Symptom prevalence, distress, and change over time in adults receiving treatment for lung cancer |
| Q74151021 | Synchroneously occurring lung cancer (stages I-II) and coronary artery disease: concomitant versus staged surgical approach |
| Q43628271 | Synchronous non-small cell lung cancers |
| Q73515325 | Temporal trends in survival after surgical resection of localized non-small cell lung cancer |
| Q41789792 | The "Kergin pneumonectomy". |
| Q40431700 | The Curative Treatment by Radiotherapy Alone of Stage I Non-Small Cell Carcinoma of the Lung |
| Q44033855 | The Lung Cancer Dilemma |
| Q77943277 | The clinical significance of hepatocyte growth factor for non-small cell lung cancer |
| Q58454753 | The close relationship between growth factors and the nucleolar organizer regions in adenocarcinoma of the lung |
| Q81574285 | The controversial role of surgery in stage III NSCLC |
| Q73174032 | The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer |
| Q73274561 | The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens |
| Q74601277 | The effect of radiotherapy on the survival of non-small cell lung cancer patients |
| Q36431605 | The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma |
| Q74369760 | The enhanced inflammatory response in non-small cell lung carcinoma is not reflected in the alveolar compartment |
| Q74267300 | The impact of delayed diagnosis of lung cancer on the stage at the time of operation |
| Q35242934 | The impact of surgery on the multidisciplinary treatment of bronchogenic small cell carcinoma (updated review including ongoing studies) |
| Q44138321 | The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer |
| Q78200374 | The management of non-small-cell lung cancer: a case history |
| Q41460428 | The multimodality treatment of stage III A/B non-small cell lung cancer. The role of surgery, radiation, and chemotherapy |
| Q53418950 | The new International Staging System for Lung Cancer. |
| Q73062614 | The prognostic application of cytokeratin typing of nonsmall cell lung carcinoma. A retrospective study |
| Q33829279 | The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy |
| Q36135375 | The relationship between weight loss and interleukin 6 in non-small-cell lung cancer |
| Q45100455 | The role of cryosurgery in palliation of tracheo-bronchial carcinoma |
| Q41600896 | The role of multimodality therapy in locoregional non-small cell lung cancer. |
| Q36135937 | The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party |
| Q69250332 | The role of surgery in N2 lung cancer |
| Q40409871 | The role of video-assisted thoracic surgery in thoracic oncological practice |
| Q38555848 | The seventh tumour-node-metastasis staging system for lung cancer: Sequel or prequel? |
| Q36573993 | The significance of pleural elastica invasion by lung carcinomas |
| Q67971291 | The sound and fury about postoperative therapy for lung cancer |
| Q73872709 | The stiffness of lymph nodes containing lung carcinoma metastases: a new diagnostic parameter measured by a tactile sensor |
| Q36391408 | The surgical management of lung cancer |
| Q36623998 | The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. |
| Q73311882 | The systemic treatment of non-small-cell lung cancer |
| Q96231168 | The top 100 cited articles in lung cancer - a bibliometric analysis |
| Q44101054 | Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy |
| Q77888972 | Time trend in the surgical management of patients with lung carcinoma |
| Q71379700 | Time trends and survival after operations for primary lung cancer from 1976 through 1990 |
| Q73794193 | Time trends and survival after surgery for p-stage IIIa, pN2 non-small cell lung cancer (NSCLC) |
| Q54681218 | Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. |
| Q47119613 | Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer |
| Q37589200 | Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials |
| Q69250378 | Treatment of superior sulcus tumor (Pancoast tumor) |
| Q37614582 | Treatment options for stage I non-small-cell lung carcinoma patients not suitable for lobectomy |
| Q44992539 | Treatment strategy for patients with surgically discovered N2 stage IIIA non-small cell lung cancer |
| Q60146493 | Trends in Small-Cell Lung Cancer Survival in 1993–2006 Based on Population-Based Cancer Registry Data in Japan |
| Q59219583 | Tumor angiogenesis and biologic markers in resected stage I NSCLC |
| Q74570507 | Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer |
| Q73815034 | Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment |
| Q43838717 | Twenty-four-hour urinary cortisol levels before complete resection of non-small cell lung cancer and survival |
| Q77730127 | Type of lymph node involvement and survival in pathologic N1 stage III non-small cell lung carcinoma |
| Q71941342 | Typical and atypical bronchopulmonary carcinoid tumors: A clinicopathologic and Kl-67-labeling study |
| Q42740334 | Unusual presentation of an uncommon lung malignancy |
| Q35667802 | Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? |
| Q67503561 | Usefulness of supraclavicular ultrasonography in the staging of lung cancer |
| Q68188581 | Utility of squamous cell carcinoma antigen (SCC Ag) as a tumour marker in pulmonary malignancy |
| Q48032721 | Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma |
| Q48461945 | Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group |
| Q40558324 | Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy |
| Q53561266 | Wedge resection for non-small cell lung cancer in patients with pulmonary insufficiency: prospective ten-year survival. |
| Q28246216 | XPC mRNA level may predict relapse in never-smokers with non-small cell lung cancers |
| Q44706237 | Young lung cancer patients in Japan: different characteristics between the sexes |
| Q70570688 | [Actuarial survival and prognostic factors of bronchial cancer] |
| Q77114582 | [Assessment of mediastinal involvement in lung cancer. Indications of mediastinoscopy, transbronchial puncture, and imaging techniques] |
| Q72191929 | [Epidermal growth factor receptor in non-small cell cancer of the lung] |
| Q52188073 | [Factors related to diagnostic reliability of bronchial biopsy in primary bronchogenic carcinoma] |
| Q80253172 | [Historic landmarks in the study of lung cancer] |
| Q74641237 | [Postoperative radiotherapy in curatively resected non-small-cell bronchial carcinoma] |
| Q73445958 | [Postoperative survival in stage II non-small-cell bronchogenic carcinoma] |
| Q73001605 | [Preoperative chemotherapy and chemoradiotherapy for non-small-cell bronchial cancers] |
| Q81320874 | [Prognosis after surgical treatment of spinal metastases due to lung cancer] |
| Q80941604 | [Results of surgery for non-small cell lung cancer with N2 involvement unsuspected before thoracotomy] |
| Q74761804 | [Results of surgical treatment of non-microcytic bronchopulmonary carcinoma in III-A stage] |
| Q78352560 | [Thoracocentesis for the assessment of lung cancer with pleural effusion] |
| Q74761795 | [Usefulness of transbronchial punction and mediastinoscopy in mediastinal nodal staging of non-microcytic bronchogenic carcinoma. Preliminary study] |
| Q77734779 | [Value and limits of surgery in stage IIIB non-small-cell bronchial cancers] |
| Q33389621 | acp. Best practice no 161. Examination of lung specimens |
| Q52922659 | bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. |
| Q63254012 | c-erbB-2 protein in serum of primary lung cancer patients |
| Q58068762 | c-mos immunoreactivity is an indicator of good prognosis in lung cancer |
| Q55158991 | p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer. |
Search more.